DexCom v. Abbott Laboratories: Federal Circuit Appeal Dismissed After 511 Days
DexCom brought an appeal before the U.S. Court of Appeals for the Federal Circuit challenging patentability decisions related to US11000213B2, a patent covering CGM analyte sensor data processing and calibration. The proceeding was voluntarily dismissed under Fed. R. App. P. 42(b) after 511 days, with each side bearing its own costs — leaving the merits unresolved on the public record.
DexCom’s Federal Circuit CGM Patent Appeal Ends Without Merits Decision
Filed on 22 February 2024, Case No. 24-1507 is an appeal before the U.S. Court of Appeals for the Federal Circuit styled as In re DexCom, Inc., with Abbott Laboratories as the opposing party. The underlying dispute centres on US11000213B2, a U.S. patent directed at systems and methods for processing analyte sensor data for sensor calibration — a core technology in continuous glucose monitoring (CGM) devices. The case arose from a patentability/invalidity challenge, consistent with an inter partes review or similar USPTO post-grant proceeding.
The Federal Circuit proceeding closed on 17 July 2025 when it was dismissed pursuant to Fed. R. App. P. 42(b), which governs voluntary dismissal at the appellate level. The court’s order specified that each side shall bear its own costs, a standard cost allocation in consensual dismissals. No merits ruling was issued — the Federal Circuit did not affirm, reverse, or vacate any underlying decision, meaning the substantive validity question was not adjudicated at the appellate level.
At 511 days, the proceeding ran for a significant period before resolution without a merits decision, suggesting negotiation or strategic reconsideration may have been underway for much of the appeal’s life. The absence of a merits ruling leaves the underlying patentability determination from the tribunal below — and its practical effect on US11000213B2 — as the operative legal outcome. The public record does not disclose whether a commercial settlement, licensing agreement, or other arrangement between DexCom and Abbott drove the dismissal.
Filing to Voluntary dismissal in 511 days
511 days from filing to voluntary dismissal at the Federal Circuit — longer than many appeal resolutions
Voluntarily dismissed: what the Fed. R. App. P. 42(b) order means for both parties
Fed. R. App. P. 42(b) ends the appeal with no merits ruling
Fed. R. App. P. 42(b) permits dismissal of an appeal by stipulation of the parties or on motion. The Federal Circuit’s order here confirms the proceeding is dismissed on this basis, meaning no appellate judgment on patentability was issued. The underlying decision from the patent tribunal below — whether it cancelled, confirmed, or partially addressed US11000213B2 — remains the operative legal outcome. The appellate record closes without precedent being set on the merits.
Procedural dismissal — no appellate meritsWith or without prejudice? The public record is silent
The court’s order records a voluntary dismissal under Rule 42(b) without specifying whether it operates with or without prejudice. These carry materially different consequences: a with-prejudice dismissal bars re-filing of the same appeal; a without-prejudice dismissal may preserve certain rights. The public docket as reflected in this record does not disclose which applies or whether a stipulation between the parties addressed this point. Practitioners should consult the full docket for any accompanying stipulation language.
Prejudice status undisclosedDexCom’s appeal ends — underlying ruling on US11000213B2 stands
As the appellant in this Federal Circuit proceeding, DexCom initiated the appeal to challenge a patentability determination affecting US11000213B2. With the voluntary dismissal, DexCom’s bid for appellate reversal is closed at this level without a favourable merits ruling. The enforceability and scope of US11000213B2 will depend on the outcome of the underlying post-grant proceeding, not this appeal. Whether DexCom retains meaningful claim coverage in the CGM calibration space requires analysis of the lower tribunal’s decision.
Appellant’s appeal closedCGM sensor calibration IP landscape remains in flux after no-merits close
DexCom and Abbott are direct competitors in the continuous glucose monitoring market. A voluntary dismissal after 511 days — with each party bearing its own costs — is consistent with a negotiated resolution, though no commercial terms are disclosed publicly. For third parties operating in CGM sensor data processing, the absence of a Federal Circuit merits ruling means no new appellate precedent was created on the patentability standards applicable to this technology. Freedom-to-operate analyses referencing US11000213B2 should focus on the lower tribunal’s ruling.
No new appellate precedentFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | In re: DEXCOM, INC. | Company | Continuous glucose monitoring technology company — holder of US11000213B2Search in Eureka ↗ |
| Defendant | Abbott Laboratories, Inc. | Company | Abbott Laboratories, Inc. — diversified medical device and diagnostics companySearch in Eureka ↗ |
| Plaintiff counsel | Elisabeth H. Hunt | Attorney | Counsel for In re: DEXCOM, INC.Search in Eureka ↗ |
| Plaintiff law firm | Wolf Greenfield & Sacks PC | Law Firm | Representing In re: DEXCOM, INC.Search in Eureka ↗ |
| Defendant counsel | Eliot Damon Williams | Attorney | Counsel for Abbott Laboratories, Inc.Search in Eureka ↗ |
| Defendant law firm | Baker Botts LLP | Law Firm | Representing Abbott Laboratories, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order is deliberately narrow: it dismisses the proceeding under Fed. R. App. P. 42(b) and allocates costs equally, but expressly declines to address the underlying patentability question. This phrasing is procedural, not substantive — the court made no finding on whether US11000213B2’s claims are valid or invalid. For both parties, the operative legal baseline reverts entirely to the outcome of the lower-level patent tribunal. The equal cost allocation is notable: it is consistent with a consensual, negotiated exit rather than a contested unilateral withdrawal.
US11000213B2 — CGM Analyte Sensor Data Processing and Calibration
US11000213B2, filed under application number US17/076716, protects systems and methods for processing analyte sensor data for sensor calibration — a foundational capability in continuous glucose monitoring technology. Sensor calibration directly affects the accuracy of glucose readings delivered to patients and clinicians, making it a commercially and clinically critical component of any CGM platform. The patent sits within a technically dense area where signal processing, algorithmic correction, and hardware-software integration converge.
In the competitive CGM market — where DexCom and Abbott’s FreeStyle Libre platform are primary rivals — calibration IP represents a meaningful differentiator. Patents protecting sensor data processing methods can affect both product performance claims and freedom to operate for new entrants developing wearable biosensors, closed-loop insulin delivery systems, and next-generation analyte monitoring platforms. The patentability challenge brought by Abbott and the subsequent Federal Circuit appeal underscore the strategic value both parties assign to this IP.
Should your team run an FTO analysis against US11000213B2?
Any organisation developing continuous glucose monitors, wearable analyte sensors, or sensor calibration software for medical or consumer health applications should assess exposure to US11000213B2. The patent’s focus on data processing methods for sensor calibration means its claims may reach beyond traditional CGM hardware to software-defined calibration approaches used in hybrid closed-loop systems, digital health platforms, and third-party CGM data integrations. The unresolved appellate history adds urgency to understanding current claim scope.
PatSnap Eureka’s FTO Search Agent enables R&D and IP teams to map active claim language from US11000213B2 against proposed product architectures, identify design-around pathways, and benchmark against the broader DexCom and Abbott CGM portfolios. With the Federal Circuit merits question unanswered, a current claim-level FTO — anchored to the lower tribunal’s final written decision — is the appropriate starting point for any organisation competing in analyte sensor data processing.
Run a freedom-to-operate analysis on US11000213B2 to assess your product’s exposure
Run FTO in Eureka →Similar CGM and Analyte Sensor Patent Appeals at the Federal Circuit
Cases involving continuous glucose monitor and analyte sensor patents at the Federal Circuit, including IPR appeals and patentability challenges in the CGM and wearable biosensor sector.
What this case signals for the CGM and wearable sensor IP landscape
A 511-day Federal Circuit appeal ending by voluntary dismissal between DexCom and Abbott carries distinct signals for CGM patent strategy and competitive positioning.
Voluntary Federal Circuit dismissals often signal off-docket commercial resolution
When two direct market competitors — DexCom and Abbott both sell competing CGM systems — drop a Federal Circuit appeal after 511 days with each party bearing its own costs, the pattern is consistent with a licensing deal, cross-licence, or commercial settlement reached before oral argument. The absence of a cost award to either side further suggests a balanced negotiated exit rather than one party capitulating unilaterally.
US11000213B2’s enforceability hinges on the underlying tribunal ruling, not this appeal
Because the Federal Circuit issued no merits ruling, the operative legal status of US11000213B2 — including whether claims were cancelled or confirmed in the underlying IPR or post-grant proceeding — determines real-world enforceability. Companies with products in CGM sensor data processing and calibration should analyse the lower-level proceeding outcome directly rather than relying on this appellate record.
In v Abbott — key questions answered
Case 24-1507 was a Federal Circuit appeal filed by DexCom on 22 February 2024, challenging a patentability determination related to US11000213B2 — a CGM sensor calibration patent. The proceeding was voluntarily dismissed under Fed. R. App. P. 42(b) on 17 July 2025, after 511 days, with each party bearing its own costs. No merits ruling was issued by the Federal Circuit.
US11000213B2, filed as application US17/076716, is a DexCom patent directed at systems and methods for processing analyte sensor data for sensor calibration in continuous glucose monitoring devices. Sensor calibration is a critical function that determines the accuracy of glucose readings, and the patent covers the data processing methods that enable reliable CGM performance.
A Rule 42(b) voluntary dismissal ends the Federal Circuit appeal without any appellate merits ruling. The court did not affirm, reverse, or vacate any lower decision. This means the legal status of US11000213B2 — including whether claims were cancelled or confirmed — is determined entirely by the outcome of the underlying patent tribunal proceeding, not this appeal.
The Federal Circuit ordered each side to bear its own costs, which is a standard outcome in voluntary dismissals and is consistent with a negotiated resolution between the parties. It suggests neither party was ordered to pay as a sanction or as a losing party cost award. The public record does not disclose whether a commercial arrangement accompanied the dismissal.
No. Because the Federal Circuit dismissed the proceeding under Rule 42(b) without issuing a merits ruling, no new appellate precedent was established on the patentability standards applicable to CGM sensor calibration technology. Third parties evaluating freedom to operate in this space cannot rely on this case for guidance on claim validity and should instead analyse the underlying lower-tribunal decision directly.
PatSnap Eureka searches patents and litigation data to answer instantly.